Xin Lang Cai Jing·2026-02-26 02:37Group 1 - The core viewpoint of the news is that Junshi Biosciences has experienced a decline in stock price and significant net outflow of funds, indicating potential investor concerns [1][2]. - As of February 26, Junshi Biosciences' stock price dropped by 2.01% to 34.05 CNY per share, with a total market capitalization of 34.959 billion CNY [1]. - The company has seen a year-to-date stock price decrease of 0.32%, with a 5-day decline of 2.80%, a 20-day decline of 3.40%, and a 60-day decline of 6.07% [2]. Group 2 - Junshi Biosciences, established on December 27, 2012, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2]. - As of September 30, 2025, the company reported a revenue of 1.806 billion CNY, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million CNY, reflecting a year-on-year growth of 35.72% [2]. - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the bioproducts sector, and is involved in various concepts including monkeypox, exclusive drugs, COVID-19 medications, and virus prevention [2]. Group 3 - As of September 30, 2025, the number of shareholders for Junshi Biosciences increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]. - Among the top ten circulating shareholders, E Fund's SSE STAR 50 ETF holds 19.3929 million shares, a decrease of 2.8203 million shares from the previous period, while Huaxia's SSE STAR 50 ETF holds 18.9720 million shares, down by 1.0745 million shares [3].